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Abstract 
The major aim of this paper was to determine whether 
cationic microspheres (CM), consisting of the permeable 
polymer Eudragit ® RS 100 plus the cationic surfactant 
dioctadecyl-dimethyl-ammonium bromide (DDAB18), 
could bind to double-stranded peptide nucleic acid PNA- 
DNA-PNA (PDP) chimeras exhibiting decoy activity 
against NF-KB transcription factors. Microspheres were 
produced by the 'solvent evaporation method' and cen- 
trifugation at 500, 1,000 and 3,000 rpm to obtain differ- 
ent-sized microparticles. Microsphere morphology, size 
and size distribution were determined by optical and 
electron microscopy observations. In order to determine 
their binding activity, double-stranded DNA-based and 
PDP-based decoy molecules were incubated with differ- 
ent amounts of microparticles in the presence of 100 ng 
of either 32p-labeled DNA-DNA or DNA-PDP hybrid mole- 
cules or cold PDP-PDP hybrids. The complexes were ana- 
lyzed by agarose gel electrophoresis. The resistance of 
32p-labeled DNA-DNA and DNA-PDP molecules in the 
presence of serum or cellular extracts was evaluated 
after binding to CM by gel electrophoresis analysis. 
DDAB18 Eudragit RS 100 microspheres are able to bind to 
DNA-PDP and PDP-PDP hybrids, to deliver these mole- 
cules to target cells and to protect DNA-PDP molecules 
from enzymatic degradation in simulated biological 
fluids. In addition, when assayed in ex vivo conditions, 
DDABm Eudragit RS 100 microspheres exhibited low tox- 
icity. The results presented in this paper demonstrate 
that CM can be considered suitable formulations for 
pharmacogenomic therapy employing double-stranded 
PDP chimeras. 
Copyright© 2004 National Science Council, ROC and S, Karger AG, Basel 
Introduction 
The transcription factor decoy (TFD) approach as 
been recently described as a very useful strategy to modify 
gene expression i the experimental reatment of human 
pathologies [1, 6, 14, 16, 19, 22, 30]. For instance, NF-~:B 
decoy oligodeoxynucleotides have been used as agents in 
acute rejection and graft arteriopathy in cardiac trans- 
plantation [16]. Furthermore, Spl decoy oligodeoxynu- 
cleotides targeting regulator?, elements of urokinase-type 
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plasminogen activator inhibit cancer metastasis [ 14]. Re- 
views on applications of the TFD approach to nonviral 
gene therapy are available in the recent literature [ 1, 6, 16, 
22]. One of the major problems of TFD is the degradation 
of DNA-based decoy molecules in serum and cellular 
extracts [ 17]. Therefore, DNA analogues resistant to exo- 
and endonucleases are of great interest [15]. 
In this respect, peptide nucleic acids (PNAs) are mole- 
cules of great interest for possible application i  pharma- 
cogenetic therapy [20]. PNAs are based on a pseudopep- 
tide (polyamide) backbone consisting of N-(2-aminoeth- 
yl)glycine units [13, 20]. Therefore, PNAs exhibit (1) the 
capacity to hybridize with high affinity to complementary 
sequences of single-stranded RNA and DNA, forming 
Watson-Crick double helices [20], and (2) resistance to 
DNAses and proteinases [8]. However, it should be em- 
phasized that PNA oligomers are characterized bya negli- 
gible TFD activity and low solubility [13]. In addition, 
PNAs are not suitable to be complexed to cationic lipo- 
somes or microspheres since, being neutrat molecules, 
they cannot form electrostatic interactions with these pos- 
itively charged systems [24]. 
With respect to the possible application of PNA-based 
molecules in gene therapy, PNA-DNA-PNA (PDP) chi- 
meras deserve gr at consideration [2, 23], due to the fact 
that they exhibit high levels of solubility and are expected 
to be resistant to proteinases and exonucleases [13]. In 
addition, we have recently reported that double-stranded 
PDP chimeras are powerful decoy molecules [3, 23]. We 
synthesized and analyzed a double-stranded PDP chi- 
mera mimicking the NF-~:B binding sites of the HIV-1 
long terminal repeat [23]. These molecules were found to 
be an excellent decoy for p52 and p50 NF-~B transcrip- 
tion factors. 
In this study, we determined whether cationic micro- 
spheres (CM), consisting of the permeable polymer Eu- 
dragit ® RS 100 plus the cationic surfactant dioctadecyl- 
dimethyl-ammonium bromide (DDAB18) [9-11], could 
bind to PDP chimeras exhibiting decoy activity against 
NF-~B transcription factors. 
Microparticles could offer a number of advantages 
compared to other delivery systems, such as liposomes, 
since they maintain unaltered chemicophysical properties 
for a long period of time, allowing long-term storage, and 
are expected to exhibit low toxicity [10]. In addition, 
depending on their composition, they could be adminis- 
tered through different routes (oral, intramuscular or sub- 
cutaneous). Finally, they are suitable for industrial pro- 
duction [t0]. 
Materials and Methods 
Synthetic Oligonucleotides and Production of NF-~cB PNA-DNA 
Chimeras 
Figure 1 shows the sequences of the produced PDP chimeI"as 
carrying binding sites for the transcription factors belonging to the 
NF-nB superfamily. NF-~B DNA-DNA was the reference decoy mop 
ecule, while PDP-DNA and PDP-PDP were the PNA-based decoy 
molecules analyzed in the present paper with respect o biological 
activity and complexation to liposomes. 
The synthetic oligonucleotides used in this study were purchased 
from Sigma (St. Louis, Mo., USA). PNA monomers for production of 
PNA-DNA chimeras were synthesized in Prof. Van Boom's laborato- 
ries [27, 28] (Leiden Institute of Chemistry, Gorlaeus Laboratories, 
Leiden University, The Netherlands). DNA monomers were ob- 
tained from Perseptive Biosystems. Methanol (Rathbum, HPLC 
grade) was stored over molecular sieves (3 A) and used without other 
purification. All the other solvents (Biosolve DNA synthesis grade) 
were used as received. Automated syntheses of the chimeras were 
performed on a Pharmacia Gene Assembler, using highly cross- 
linked polystyrene (loading 26-28 gmol/g) as the solid support on a 
1-pmol scale, as reported elsewhere [23]. After the last elongation 
step, the oligomers were cleaved from the solid support and depro- 
tected by treatment with 1.5 ml of methanolic ammonia t 50 o C for 
16 h. The samples were filtered and then purified by RP-HPLC on a 
LiChrosphere 100 RP-18 end-capped column (4 x 250 mm) on a 
Jasco HPLC system. Gradient elution was performed at 40 ° C, build- 
ing up the gradient starting with buffer A (50 mM triethylammonium 
acetate in water) and then applying buffer B (50 mM triethylammo- 
nium acetate in acetonitrile-water, 1/1, v/v, with a flow rate of 1 ml/ 
rain). Chimera 1: HPLC purity 100%, tR = 18 rain (gradient 3-20% B 
in 25 rain); chimera 2: HPLC purity 100%, tR = 16 rain (gradient 
5-25% B in 25 rain). HPLC-MS analysis was carried out on a Jasco 
LCMS system equipped with a LiChrosphere 100 RP-18 end-capped 
column (4 x 250 ram) using a gradient of acetonitrile in 10 mM 
ammonium acetate buffer with mass detection on a Perkin Elmer 
Sciex API 165 equipped with an Electrospray Interface (ESI). 
Chimera 1: tR = 7 rain (gradient 5-20% acetonitrile in 29 rain); 
ESI-MS: [M+4H] 4+ = 1,438.2, [M+5H] 5+ = 1,150.5, calculated for 
CI93Hz45N90095P13 5,748,26. Chimera 2: ta = 8 rain (gradient 0-20% 
acetonitrile in 20 rain); ES1-MS: [M+4H] 4+ = 1,443.6, [M+SH] 5+ = 
1,154.9, calculated for C194H247N86099P13 5,770.26. 
Sequences: chimera 1: Gly-ccg-5'TGGAAAGTCCCCA3'-gcg-Ac; 
chimera 2: Gly-cgc-5'TGGGGACTTTCCA3'-cgg-Ac. 
Production of Cationic Microparticles 
The polymer used for microparticle preparation was the acrylic 
resin Eudragit RS 100 fi'om Rohm Pharma (Darmstadt, Germany). 
The cationic surfactant DDAB18 was from Fluka (Buchs, Switzer- 
land). Microparticles were produced by the 'solvent evaporation 
method' as described in detail elsewhere [11]. Briefly, 500 mg of a 
100:30 (w/w) complex of Eudragit RS 100 and DDABI8 were dis- 
solved in 5 ml of CH2C12. The solution was emulsified with 100 ml of 
an aqueous phase containing 1% (w/v) of 88 % hydrolyzed polyvinyl 
alcohol (Airvo1205, Air Products, Pa., USA) as dispersing agent (Ika 
Labortechnick, Germany). After complete evaporation of CH2C12, 
microparticles were isolated by centrifugation at 500, 1,000 and 
3,000 rpm. Microparticte morphology, size and size distribution 
were determined by optical and electron microscopy observations as 
described elsewhere [ 11 ]. 









5'-CGC TGGGGACTTTCCA CGG-3' DNA-PDP 
Ac.GCG-3,-ACCCCTGAAAGGT.5,-GCC.Gly~n 2 hybrid 
Fig. 1. Structure and sequences of the decoy molecules used in this 
study, based on DNA or PDP chimeras. The sequences are recog- 
nized by transcription factors belonging to the NF<B family. DNA 
segment spans from 5'- to 3'-termini. The protocol for the synthesis 
of PNA oligomers on a 1-gmol scale has been described elsewhere. 
Complexation f NF-trB DNA-DNA, DNA-PDP and PDP-PDP 
Hybrids to Microspheres 
Different amounts of microparticles were incubated in the pres- 
ence of 100 ng of either 32p-labeled DNA-DNA or DNA-PDP hybrid 
molecules or cold PDP-PDP. The complexes were etectrophoresed 
through an agarose gel and exposed to ma autoradiographic procedure 
(in the case of DNA-DNA and DNA-PDP molecules) or stained with 
ethidium bromide (in the case of PDP-PDP molecules) [23]. 
Resistance ofDecoy Molecules 
The resistance of 32p-labeled DNA-DNA and DNA-PDP target 
molecules was evaluated as follows. The decoy molecules were incu- 
bated without or with different amounts of microspheres (2-25 gg/ 
reaction) for 30 min at room temperature, and then serum (fetal calf 
serum, Eurobio, France) was added (3 pl/reaction). After overnight 
incubation, the reactions were phenol extracted, ethanol precipitated 
and electrophoresed through apolyacrylamide g l, and autoradiogra- 
phy was performed. Disappearance of the decoy molecule band was 
considered evidence of degradation by the employed nzymes [3]. 
We always premixed unlabeled PCR products or oligonucleotides 
just before phenol extraction i  order to control the recovery. 
Cell Lines and Culture Conditions 
Human erythroleukemia K562(S) cells were cultured in a humid- 
ified atmosphere at5 % CO2 in RPMI- 1640 (Flow Laboratories) up- 
plemented with 10% fetal bovine serum (CELBIO), 50 units/ml peni- 
cillin and 50 gg/ml streptomycin. The effects of DDABls Eudragit 
RS 100 microspheres on in vitro cell growth were determined after 
3 days by an MTT-based colorimetric assay. In order to determine 
the uptake of DNA-PDP chimeras in living cells, chimera 2 was 
annealed to an equal amount of the complementary 5'-fluorescein- 
labeled DNA and, after 16 h, the molecules were fractionated by elec- 
trophoresis onto a 10% polyacrylamide g l. Bands corresponding to 
the annealed DNA-PDP were electroeluted and concentrated bycen- 
trifugation onto microcon-3 tubes (Amicon, Millipore Corporation, 
Bedford, Mass., USA). Four hundred nanograms of DNA-PDP were 
incubated with 320 gg of DDAB 18 Eudragit RS 100 microspheres for 
20 min in PBS at room temperature and, after this time, the mixture 
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Fig. 2. Comparison of the complexation efficiencies ofNF-~cB DNA- 
DNA and NF-•B DNA-PDP hybrids to CM. The indicated amounts 
of microspheres were incubated in the presence of 32p-labeled DNA- 
DNA or DNA-PDP hybrid molecules, and complexes formed were 
fractionated by eIectrophoresis through an agarose gel and exposed to 
autoradiography. Arrows indicate material bound to microspheres. 
f-- Free decoy molecules. 
was added to 4 ml of complete medium containing 1 x 106 cells. 
Aliquots of 1 ml each were collected 2, 8 and 24 h later, washed 3 
times with PBS, spotted onto poly-lysine-coated microscope slides 
and fixed. Mounted slides were observed at x 2,000 on an Olympus 
BX60 fluorescence microscope. 
Results 
Complexation of Double-Stranded DNA-PNA 
Chimeras to Microsp,~eres 
Figure 2 shows that  CM b ind  to DNA-PDP hybr ids.  
This  is demonst ra ted  by the format ion,  when high con- 
centrat ions o f  CM were used (5-10/.tg/react ion),  o f  com- 
plexes ( ident i f ied as bound mater ia l )  unable  to migrate 
into the gels. It should be noted that complexat ion  of  
NF-~zB DNA-PDP to microspheres  is somewhat  lower 
Complexation ofPNA-DNA Chimeras to 
Microspheres 
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Fig. 3. a Binding of PDP-PDP molecules to 
increasing amounts of CM prepared by cen- 
trifugation at 3,000 rpm. Unlabeled PDP- 
PDP hybrids (arrows) were detected by aga- 
rose gel electrophoresis and ethidium bro- 
mide staining, A representative experiment 
was reported, b Quantitative determination 
of free DNA-DNA ((3) and PDP-PDP (0)  
hybrids after the addition of increasing 
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than the complexation of NF-~cB DNA-DNA hybrids to 
this CM formulation. Furthermore, PDP-PDP hybrids 
efficiently bind to CM isolated by centrifugation at 
3,000 rpm, even if showing binding affinity somewhat 
lower than that exhibited by DNA-DNA hybrids (fig. 3). 
In this case, due to the difficulty of obtaining 32p-labeled 
PDP-PDP chimeras, unlabeled PDP-PDP molecules 
were used and the gels were stained with ethidium bro- 
mide. 
This finding allows us to propose microspheres for pos- 
sible use in nonviral gene therapy for delivery of PDP- 
based molecules to target cells on the one hand and for the 
possible protection of PDP molecules in biological fluids 
after comptexation with microspheres. This latter possi- 
bility is of great interest for in vivo delivery. Furthermore, 
protective effects in cellular extracts are also important as 
decoy molecules are expected to exert heir effects only if 
sufficient stability allows their localization in the nuclear 
compartment. In light of these considerations, therefore, 
it is imperative to demonstrate (1) uptake by cultured 
cells and (2) possible protective ffects in the presence of 
high amounts of serum and cellular extracts. 
Uptake of DNA-PDP Hybrids by Cultured K562 Cells 
In these experiments, ftuorescein-labeled DNA was 
employed and annealed with complementary PDP chi- 
meras. The hybrid double-stranded molecules (NF-~:B 
DNA-PDP) were bound to an excess of DDAB~8 Eudragit 
RS 100 microspheres (3,000 rpm) and cultured for in- 
creasing lengths of time (2, 8 and 24 h) with human leu- 
kemic K562 cells. After 2 h, microspheres loaded with flu- 
orescein-labeled DNA-PDP NF-~zB chimeras are visible 
as bodies attached to cells (fig. 4, upper panels). Interest- 
ingly, after 8 h, the fluorescent molecules are visible in the 
cytoplasm (fig. 4, middle panels), and after up to 24 h, 
they- are widely distributed into the cells (fig. 4, lower 
panels). Fluorescein-labeled DNA-PDP molecules recov- 
ered after these xperiments were found to maintain their 
double-stranded structure (data not shown). 
Protective EfJects of Microspheres on Double-Stranded 
DNA-PNA Chimeras 
In order to verify whether the observed binding of 
PNA-based decoy molecules to CM leads to protective 
effects, the experiment illustrated in figure 5 was per- 
formed. In this experiment, DNA-PDP and DNA-DNA 
molecules were used, since PDP-PDP hybrids are resis- 
tant in serum and cellular extracts even in the absence of 
microspheres [5 ]. 
When 32p-labeled DNA-PDP chimeras or DNA-DNA 
molecules were incubated in serum overnight in the 
absence of microspheres, degradation of32P-labeled DNA 
was observed (fig. 5, filled arrows). By contrast, when the 
DNA-PDP chimeras or DNA-DNA molecules were incu- 
bated with increasing amounts of CM (20-140 gg), before 
the addition of serum (fig. 5, left panels) or cellular 
extracts (fig. 5, right panels), they were protected from 
degrading enzyme activity, and the size of recovered 
DNA (filled arrows in fig. 5) was identical to that of 
untreated molecules, howing that no enzymatic degrada- 
tion of DNA-PDP molecules occurs after complexation to
CM. Results similar to those shown in figure 5 were 
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Fig. 4. Uptake of DNA-PDP chimeras in K562 cells. Fluorescein-labeled DNA-PDP hybrids were bound to 
CM prepared by centrifugation at 3,000 rpm. The complexes were added to the cells in culture medium and 
aliquots were collected after 2, 8 and 24 h. Representative fields from different time points are shown. Left 
panels: phase contrast. Right panels: fluorescence. Black arrows indicate the microspheres; white arrows 
indicate the cells. 
Complexation fPNA-DNA Chimeras to 
Microspheres 
J Biomed Sci 2004;11:697-704 701 
Fig. 5. Protective effects of CM, prepared by 
centrifugation at 3,000 rpm, on 32P-labeled 
NF-~B DNA-DNA and DNA-PDP target 
molecules. DNA-DNA and DNA-PDP tar- 
get molecules were incubated without (w/o) 
CM or with increasing amounts (shown as 
gg/reaction) ofCM for 30 rain at room tem- 
perature, and then serum (left panels) or 
K562 cellular extracts (right panels) were 
added (3 gl/reaction for serum and 1 gg/ 
reaction for cellular extracts). After an over- 
night incubation, the molecules were puri- 
fied by phenol extraction and separated by 
electrophoresis on denaturing polyacryl- 
amide gel. Filled arrows indicate the migra- 
tion of intact DNA molecules. 
wells line t> 
front line t> 
wells line t> 
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obtained by repeating the experiments with commercially 
available nzymes (data not shown). 
Effects of CM on Cell Growth 
The effects of CM on ex vivo cell growth of the human 
leukemia K562 cell line were determined by an MTT- 
based colorimetric assay. In order to perform a compari- 
son with commercial delivery systems for DNA, lipofec- 
tin and cellfectin were also included in the experiment. 
The results of the experiment are shown in figure 6. As is 
clearly appreciable, a low antiproliferative ffect was 
shown in the presence of CM. In contrast, it should be 
emphasized that lipofectin and cellfectin displayed a 
higher antiproliferative activity (fig. 6). 
Discussion 
Fig. 6. Effects of microspheres on cell growth. K562 cells were cul- 
tured in the absence or in the presence of the indicated amounts of 
microspheres, eparated by centrifugation at 3,000 rpm (CM-3000), 
1,000 rpm (CM-1000) or 500 rpm (CM-500), or common commer- 
cially available cationic lipids (lipofectin or cellfectin). After 3 days, 
the cell number/ml was determined in treated cells and compared to 
that of control cells. 
In spite of the number of possible advantages over 
commonly used nucleic acids, PNAs present two major 
drawbacks: (1) being neutral molecules, they are not suit- 
able for efficient delivery with nonviral cationic formula- 
tions (liposomes, dendrimers, polymers) [24], and (2) they 
are not useful for TFD therapy, one of the most interest- 
ing approaches to c ntrolling ene expression [4, 7, t3, 
18]. Interestingly, we have recently demonstrated that 
DNA-PNA hybrids carrying the HIV-1 long terminal 
repeat NF-~zB binding site bind to the NF-~:B factor puri- 
fied or present within nuclear extracts, although the com- 
702 J Biomed Sci 2004;11:697-704 Mischiati et al. 
plex formed is only weakly stable [18]. In addition, we 
have demonstrated that PNA-DNA chimera hybrids in- 
teract with transcription factors NF-~B and Spl in a sta- 
ble manner [4, 23]. Furthermore, PDP chimeras are resis- 
tant to exonucleases [ 13] and are active in inhibiting inter- 
actions between transcription factors and DNA [4, 5, 23, 
24]. However, in order to improve cellular uptake and sta- 
bility in biological fluids, an efficient strategy to deliver 
PNA-DNA chimeras is highly recommended. 
With this aim, we set out to determine whether micro- 
spheres could efficiently bind to PNA-DNA chimeras 
exhibiting decoy activity. Instead of PNAs, which, being 
neutral molecules, are not suitable to be complexed to cat- 
ionic liposomes or microspheres, we used PNA-DNA chi- 
meras, which are charged molecules and could form elec- 
trostatic interactions with these positively charged sys- 
tems. 
The results presented in this paper demonstrate that 
CM of different sizes (fig. 2) bind to PNA-DNA chimeras 
with an efficiency comparable to DNA molecules 
(fig. 2, 3) and thus represent a useful vehicle for the in 
vitro delivery of PDP-PDP and DNA-PDP decoy hybrids 
carrying NF-~:B binding sites to target cells. In addition, 
CM were found to exhibit low cytotoxicity when com- 
pared to commercial liposome formulations (fig. 6) and to 
protect DNA-PDP hybrids from enzymatic degradation 
in biological fluids (fig. 5). This is a very important prob- 
lem in gene therapy based on the use of DNA and DNA 
analogues [31, 33]. 
These results are clearly complementary to those al- 
ready reported by our research group using liposomes as 
delivery systems [3]. It is to be emphasized that micropar- 
ticles and liposomes are complementary delivery systems. 
In fact, liposomes are excellent delivery systems in sys- 
temic treatments [26, 32]. On the other hand, microparti- 
cles, by reason of their larger dimensions (30-300 ~tm), 
stability and high drug loading, are particularly useful for 
therapeutic approaches involving chemoembolization [2, 
12] and subcutaneous implants [25]. Interestingly, both 
systemic and local administration routes for TFD mole- 
cules targeting NF-•B transcription factors are de- 
manded. For instance, systemic administration of NF-~:B 
decoy oligodeoxynucleotides reduces monocyte infiltra- 
tion in renal allografts [29]. On the other hand, local 
administration of decoy molecules targeting NF-~cB fac- 
tors cotfld be of great interest for experimental therapy of 
periodontitis or osteopenic diseases [21]. 
The results presented in this paper are thus of practical 
importance, since the simplicity and the versatility ofCM 
technology has made these reagents useful nonviral gene 
delivery systems for human gene therapy [11]. In this 
respect, further studies are in progress in order to assess 
the ex vivo effectiveness of microspheres for PNA-DNA 
chimera dministration. 
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